Who, What, Where

Liam Patrick was named managing director of Fireman Capital Partners, or FCP, a private equity firm based in Boston. Patrick will be responsible for merger-and-acquistions and investor relations activities for FCP and its investment vehicles. Prior to joining FCP, Patrick worked for private equity firm Rhône Group. FCP was founded in 2008 by Paul Fireman, Dan Fireman, and Andrew Spellman. Paul Fireman sold Reebok International Ltd., a Canton-based athletic footwear and apparel company, to Adidas-Salomon AG in 2006 for $3.8 billion. Paul Fireman and his wife, Phyllis, stood to make nearly $800 million from the sale.

Kevin Gray is the new chief technology officer at Qteros, a Marlborough company that has developed technology that turns biomass into cellulosic ethanol. Gray most recently served as senior director of biofuels research and development for biotech company Verenium Corp.

Fred Sammartino and Timothy Moynihan have new executive jobs at Empirix Inc., a Bedford company that specializes in service quality assurance solutions for new IP communications. Sammartino was appointed vice president of marketing and product management for the company's service assurance business unit, where he will be responsible for extending its global reach. Moynihan joined the company as vice president of marketing for the contact center solutions business unit, where he will be responsible for strategic business planning and product revenue growth strategies. Sammartino previously served as vice president of marketing and product management for Ellacoya Networks, and Moynihan served as vice president of global marketing and channels at Envox Worldwide.

Alex Chu has been named vice president of process development at Microbia Inc. Headquartered in Lexington, Microbia is an industrial biotechnology company applying proprietary metabolic engineering utilizing fermentation technology to create cost-effective, renewable specialty ingredients and biomaterials. Chu was most recently the vice president of manufacturing and process development at Adnexus Therapeutics.